Wells Fargo & Company assumed coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) in a note issued to investors on Friday, Marketbeat reports. The brokerage set an “overweight” rating and a $54.00 price target on the specialty pharmaceutical company’s stock. Wells Fargo & Company‘s price target points to a potential upside of 88.75% from the company’s current price.
Other equities analysts have also recently issued reports about the company. Weiss Ratings upgraded Supernus Pharmaceuticals from a “sell (d-)” rating to a “hold (c+)” rating in a report on Friday, November 13th. Jefferies Financial Group began coverage on Supernus Pharmaceuticals in a report on Wednesday, November 4th. They set a “strong-buy” rating for the company. Bank of America initiated coverage on Supernus Pharmaceuticals in a research report on Monday, November 9th. They issued a “buy” rating and a $47.00 price target for the company. Cantor Fitzgerald lifted their price target on Supernus Pharmaceuticals from $67.00 to $87.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Finally, Piper Sandler started coverage on Supernus Pharmaceuticals in a report on Wednesday, November 4th. They set an “overweight” rating and a $47.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $59.17.
Read Our Latest Analysis on Supernus Pharmaceuticals
Supernus Pharmaceuticals Trading Up 0.9%
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) last released its earnings results on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). The business had revenue of $208.60 million during the quarter, compared to the consensus estimate of $217.56 million. Supernus Pharmaceuticals had a negative return on equity of 418.04% and a net margin of 32.75%. The firm’s revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.80) earnings per share. On average, research analysts forecast that Supernus Pharmaceuticals will post 3.80 earnings per share for the current year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of SUPN. BlackRock Inc. purchased a new stake in Supernus Pharmaceuticals in the 2nd quarter worth about $434,871,000. Stephens Investment Management Group LLC grew its stake in Supernus Pharmaceuticals by 10.2% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,638,047 shares of the specialty pharmaceutical company’s stock valued at $58,724,000 after acquiring an additional 152,226 shares in the last quarter. GW&K Investment Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 32.5% in the 3rd quarter. GW&K Investment Management LLC now owns 1,374,198 shares of the specialty pharmaceutical company’s stock valued at $49,265,000 after purchasing an additional 336,956 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Supernus Pharmaceuticals by 36.1% in the 3rd quarter. Goldman Sachs Group Inc. now owns 1,115,001 shares of the specialty pharmaceutical company’s stock valued at $39,973,000 after purchasing an additional 295,569 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Supernus Pharmaceuticals by 37.2% in the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after purchasing an additional 193,479 shares during the period.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. Its work spans neurology and psychiatry, including therapies for epilepsy, attention-deficit/hyperactivity disorder (ADHD), and Parkinson’s disease. The company’s marketed products include Qelbree for ADHD; Oxtellar XR and Trokendi XR for epilepsy; and medicines for Parkinson’s disease, including Apokyn, Xadago, and Ongentys. Its portfolio also includes Gocovri, which is used to treat certain movement complications associated with Parkinson’s disease.
Further Reading
- Five stocks we like better than Supernus Pharmaceuticals
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
